(Q34448363)

2 August 2017

Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex (English)

1 reference

2 August 2017

1 reference

P A Pierce

1

1 reference

2 August 2017

S J Peroutka

series ordinal

2

1 reference

2 August 2017

language of work or name

1 reference

1 January 1989

1 reference

2 August 2017

1 reference

2 August 2017

97

1 reference

2 August 2017

118-122

1 reference

2 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00443425

2 August 2017

0 references

cites work

Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents

1 reference

12 December 2020

Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists

1 reference

12 December 2020

Hallucinogen binding to dopamine/neuroleptic receptors

1 reference

12 December 2020

Guanyl nucleotide and divalent cation regulation of cortical S2 serotonin receptors.

1 reference

12 December 2020

Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus

1 reference

12 December 2020

Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions.

1 reference

12 December 2020

Nerve terminal effects of indoleamine psychotomimetics on 5-hydroxytryptamine

1 reference

12 December 2020

Cross generalization with LSD and yohimbine in the rat.

1 reference

12 December 2020

[3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.

1 reference

12 December 2020

Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies.

1 reference

12 December 2020

Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats

1 reference

12 December 2020

Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat.

1 reference

12 December 2020

Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex.

1 reference

12 December 2020

R(?)-2,5-Dimethoxy-4-77bromoamphetamine [77Br-R(?)DOB]: a novel radioligand which labels a 5-HT binding site subtype

1 reference

12 December 2020

A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist.

1 reference

12 December 2020

Mescaline and LSD: Direct and indirect effects on serotonin-containing neurons in brain

1 reference

12 December 2020

Antagonism of the LSD cue by putative serotonin antagonists: relationship to inhibition of in vivo [3H]spiroperidol binding.

1 reference

12 December 2020

Training dose as a factor in LSD-saline discrimination.

1 reference

12 December 2020

5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants.

1 reference

12 December 2020

Action of psychotogenic drugs on single midbrain raphe neurons

1 reference

12 December 2020

Indolealkylamine and phenalkylamine hallucinogens: a brief overview

1 reference

12 December 2020

Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes

1 reference

12 December 2020

The use of drug discrimination procedures to characterize hallucinogenic drug actions.

1 reference

12 December 2020

Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol

1 reference

12 December 2020

3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00443425

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference